Ambrosia Biosciences raised an oversubscribed $100 million Series B to advance its preclinical oral obesity pipeline into Phase I. The round co-led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital will support Ambrosia’s lead oral GLP-1–targeting program and additional work around GIP and amylin. The financing comes after the company formation period tied to Pfizer’s acquisition-driven facility shutdown, positioning Ambrosia to compete in a crowded oral obesity space where differentiation increasingly hinges on oral delivery, tolerability, and combination potential. Separately, Syneron closed a $150 million Series B to expand its macrocyclic peptide development platform—an additional signal that investors are continuing to fund modality diversification beyond the GLP-1 wave.